INVESTORS

Our model was designed to reduce investment risk in life sciences projects, increase profits, and generate social impact

LAB+ –the company builder that began its investments at the end of 2023– offers investors the chance to engage in impactful ventures by collaborating with leading global researchers in life sciences. Our long-term capital investment strategy aims to yield attractive returns while advancing the field significantly.
Our portfolio start-ups provide innovative solutions to real societal problems in the medical and environmental sectors, enhancing everyone’s quality of life and giving investors an excellent opportunity to make a meaningful impact.

 

We believe in the exceptional talents and capabilities of scientists and entrepreneurs in Latin America and aim to be their ideal partner by leveraging our unique scientific expertise with a business-oriented investment approach.
Our investments target a diverse range of sectors within the life sciences industry, including:

• Drug Discovery & Pharmaceuticals
• Ag-Tech & Food-Tech
• Med-Tech
• Healthcare Services
• Diagnostics and Biomedicine

We have proven expertise through a team that comprises seasoned professionals with deep knowledge in the life sciences sector, ensuring informed investment decisions and strategic guidance for our portfolio companies.
We have an innovative focus that prioritizes investments in cutting-edge technologies and therapies that would potentially revolutionize healthcare; as well as a collaborative approach working closely with our portfolio companies, providing strategic support, industry connections, and operational insights to accelerate their growth.

De-risking: the strategy to minimize risks

LAB+ de-risking model involves one to one mentorship sessions with the founders to develop a solid action plan to implement their innovations in the field of action by strategic planning. This includes extensively market analysis, to identify and perform feasibility studies and pilot projects to test the viability of ideas before significant resources are committed. We also offer comprehensive operational support, including communication, legal, and administrative services, allowing the founders to advocate to their core activities and reduces the operational burden on founding teams.

As a venture builder LAB+ also provide capital and strategic financial support and planning to support their growth, reducing the risk of cash flow problems and providing a safety financial background for early-stage startups.

Our success stories are the catalysts behind the creation of LAB+

The Institut Pasteur de Montevideo—founded in 2006—began in 2016 with the idea of using knowledge to help society by applying a start-up development model. In an ecosystem where science and knowledge generation primarily had an academic profile, the institute ventured to implement various programs that, after a successful learning curve, have resulted in several created companies and notable success stories.

One of the most relevant is Eolo Pharma. Jointly driven by the General Partners (GPs) of LAB+, this pharmaceutical company focuses on developing new therapies for cardiometabolic, neurodegenerative, and autoimmune disorders.

It has successfully advanced an original therapeutic compound to human clinical trial phases. This achievement has been a national milestone and has positioned its leading compound, a drug for the prevention and treatment of obesity and its associated metabolic diseases, as an innovative therapy on a global scale.

Initially invested in by CITES and with its R&D laboratories housed at the Institut Pasteur of Montevideo, Eolo Pharma continued its development journey with support from Ficus Advisory, which led the Series A funding round in 2019 to support the start-up’s growth.